BRPI0417108A - métodos de tratamento de rejeições de transplantes em pacientes - Google Patents

métodos de tratamento de rejeições de transplantes em pacientes

Info

Publication number
BRPI0417108A
BRPI0417108A BRPI0417108-0A BRPI0417108A BRPI0417108A BR PI0417108 A BRPI0417108 A BR PI0417108A BR PI0417108 A BRPI0417108 A BR PI0417108A BR PI0417108 A BRPI0417108 A BR PI0417108A
Authority
BR
Brazil
Prior art keywords
patients
methods
transplant rejection
treating transplant
treating
Prior art date
Application number
BRPI0417108-0A
Other languages
English (en)
Inventor
Paul G Brunetta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0417108A publication Critical patent/BRPI0417108A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

"MéTODOS DE TRATAMENTO DE REJEIçõES DE TRANSPLANTES EM PACIENTES". A presente invenção descreve um método de tratamento de rejeição de transplantes em pacientes, em que CD20 é detectado em uma de suas amostras.
BRPI0417108-0A 2003-12-19 2004-12-07 métodos de tratamento de rejeições de transplantes em pacientes BRPI0417108A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53159403P 2003-12-19 2003-12-19
PCT/US2004/040947 WO2005061542A2 (en) 2003-12-19 2004-12-07 Detection of cd20 in transplant rejection

Publications (1)

Publication Number Publication Date
BRPI0417108A true BRPI0417108A (pt) 2007-02-06

Family

ID=34710237

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417108-0A BRPI0417108A (pt) 2003-12-19 2004-12-07 métodos de tratamento de rejeições de transplantes em pacientes

Country Status (11)

Country Link
US (1) US20050191297A1 (pt)
EP (1) EP1697419A2 (pt)
JP (1) JP2008507473A (pt)
KR (1) KR20060107555A (pt)
CN (1) CN1918181A (pt)
AU (1) AU2004303848A1 (pt)
BR (1) BRPI0417108A (pt)
CA (1) CA2549237A1 (pt)
MX (1) MXPA06006865A (pt)
RU (1) RU2006126099A (pt)
WO (1) WO2005061542A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
EA036531B1 (ru) 2003-11-05 2020-11-19 Роше Гликарт Аг Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
EP1735000A2 (en) * 2004-04-16 2006-12-27 Genentech, Inc. Method for augmenting b cell depletion
PL2178916T3 (pl) * 2007-07-31 2015-08-31 Regeneron Pharma Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
WO2012065755A1 (en) * 2010-11-19 2012-05-24 Bavarian Nordic A/S Production of ifn-lambda by b cells
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2016081490A1 (en) 2014-11-17 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
JP2018520153A (ja) * 2015-06-29 2018-07-26 ジェネンテック， インコーポレイテッド 臓器移植における使用のためのｉｉ型抗ｃｄ２０抗体
EP3844189A1 (en) 2018-08-31 2021-07-07 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
RU2728683C1 (ru) * 2019-12-03 2020-07-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) Способ ранней диагностики отторжения трансплантата

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
CA2149329C (en) * 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
EP1112084B2 (en) * 1998-08-11 2012-04-25 Biogen Idec Inc. Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
US6383276B1 (en) * 1999-03-12 2002-05-07 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
US7074403B1 (en) * 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
JP2003528805A (ja) * 1999-07-12 2003-09-30 ジェネンテック・インコーポレーテッド Ｃｄ２０に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
KR20020091170A (ko) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
ES2528794T3 (es) * 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
CN1437478A (zh) * 2000-04-25 2003-08-20 Idec药物公司 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
WO2001097843A2 (en) * 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
DE60239931D1 (de) * 2001-04-02 2011-06-16 Genentech Inc Kombinationstherapie
EP2131198B1 (en) * 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
ES2326964T3 (es) * 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20030219818A1 (en) * 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy

Also Published As

Publication number Publication date
AU2004303848A1 (en) 2005-07-07
CN1918181A (zh) 2007-02-21
KR20060107555A (ko) 2006-10-13
JP2008507473A (ja) 2008-03-13
RU2006126099A (ru) 2008-01-27
WO2005061542A2 (en) 2005-07-07
EP1697419A2 (en) 2006-09-06
MXPA06006865A (es) 2006-08-23
WO2005061542A3 (en) 2005-12-29
US20050191297A1 (en) 2005-09-01
CA2549237A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
TW200716141A (en) Compositions and methods for treatment for neoplasms
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DE50312145D1 (de) Vorrichtung zur behandlung von frakturen des femur
DE602006004009D1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
BRPI0514017A (pt) indazóis úteis no tratamento de doenças cardiovasculares
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE602005017373D1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
ECSP066635A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
DE602004017037D1 (de) 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE519503T1 (de) Verfahren zur behandlung von patienten mit hepatitis c
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ATE556707T1 (de) Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
DE602007010459D1 (de) Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie
DE502008003215D1 (de) Mittel und verfahren zur gerbung von häuten und fellen
DE50209932D1 (de) Verfahren und kit zur diagnostik oder behandlungskontrolle von darmkrebs
DE20320825U1 (de) Vorrichtung zur Aufbereitung von Kunststoffabfällen
ATE364389T1 (de) Verfahren zur herstellung von extrakten aus pelargonium sidoides und/oder pelargonium reniforme

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.